Some animals seem to appreciate music. What does that mean for human evolution?
Ronan the sea lion can dance to a lot of different songs, but there is something about 'Boogie Wonderland,' by Earth, Wind and Fire that really gets her going.
It didn't take more than a few days for Peter Cook, a marine mammal sciences professor at the New College of Florida, to train Ronan to bop her head to music. Using fish as a reward, he taught her the movement. Then he taught her to move when a metronome played. Over the course of the next two months, he gave her a fish every time she synchronized her head bops to the beat of the music. Once that clicked, she could do it 60 times in a row within a couple of days, he said.
Before long, she was able to do this with music recorded live in a studio with natural fluctuations, complex instrumentation and syncopation, meaning different beats were emphasized in different measures, Cook explained. And it wasn't just Earth, Wind and Fire that got her moving, but also the Backstreet Boys and other rock songs.
'Once she understood the task, she seemed to be able to transfer that knowledge over to even complex musical types of stimuli, which do have things like meter,' Cook told Salon in a phone interview. 'The thing is, we're just not sure how she thinks about or understands things like meter, syncopation or anything like that.'
Historically, many thought that humans were the only animals that could recognize an external beat and synchronously move to it. But in 2007, Snowball the cockatoo went viral for dancing to the rhythm of the Backstreet Boys. Then, in 2013, Ronan the sea lion similarly acquired world-fame for moving her head rhythmically to the beat of music.
These two case studies are part of a growing field of research set on trying to understand which animals have the capacity to be musical, providing clues on how and why music evolved in humans.
In 1871, Charles Darwin wrote: "The perception, if not the enjoyment, of musical cadences and of rhythm is probably common to all animals.' Darwin suggests that if music gives us pleasure, it has an evolutionary purpose. And if all animals share a common ancestor, it could be something that is evolutionarily shared. But that isn't easy to investigate.
'We have this problem in studying the origins of musicality … Music doesn't fossilize,' said Henkjan Honing, a professor of Music Cognition at the University of Amsterdam. 'Cross-species work is a way of resolving that problem because the assumption is that if you share a certain trait with a genetically close species, then the common ancestor might also have had that particular skill.'
In a way, all animals make rhythms, whether in the form of fireflies flashing, birds chirping or even a tiger pacing back and forth. Some of these rhythms are influenced by pure physiology: Walking, swimming and having a heartbeat are all rhythmic. Yet defining what constitutes music is challenging because it is inherently subjective. Plus, we don't know if animals experience music as music, or if that is our own human experience we are projecting onto them.
In one study released last month, eastern and western chimpanzees — which are two different subspecies — were observed in the wild to have distinct drumming patterns. These patterns are short, structured and rhythmic, but they are thought to be used more for communication purposes than for music, said study author Vesta Eleuteri, who studies the evolution of social cognition and communication at the University of Vienna.
'Some chimpanzees drum with isochrony [occurring at the same time], but we didn't find evidence of other core musical rhythms that are present in humans,' Eleuteri told Salon in a video call.
Musicality generally implies that animals have control over the rhythm they are making and use it flexibly. One way to determine if an animal is musical is to see if they have the ability to identify a note's pitch in relation to other notes. Another way, which has been studied more, is to see if they are capable of synchronizing to beats in a rhythm, Honing said.Human children have been shown to do this before they can walk or talk, though it's unclear whether this ability is learned or innate. Children aren't perfectly synchronized to the beat at younger ages and they improve over time, suggesting that it could be something that is socially learned. On the other hand, one 2009 study found evidence in baby's brains that they were detecting rhythmic patterns as young as seven months old, which could indicate that this ability is already functional at birth.
Nevertheless, in a study published in May, Ronan the sea lion was shown to perform better than adult humans when tasked with moving in sync to a beat. Although Ronan doesn't perform this task outside of her training sessions on her own, she does get a fish regardless of whether or not she moves to the music in training sessions, indicating she is voluntarily moving to the beat, Cook said.
It's unclear what motivates Ronan to perform this activity, but Cook said sea lions are kind of like the Border Collies of the sea and can quickly learn new tasks. As such, it could have something to do with mastering a task, he explained.
'I think she enjoys the cognitive challenge and the opportunity to sort of master something and then practice that mastery,' he said. 'I just don't know if it's about groove the way it is with humans.'
Looking at similarities and differences between our closest living relatives, primates, can provide clues into whether music shares a common ancestral origin. In humans, if we are walking or typing and listening to music, we naturally sync up to the rhythm. In studies conducted by Yuko Hattori, an assistant professor at Kyoto University's Primate Research Institute, chimpanzees were able to synchronize their movement to a variety of rhythms. Similar findings were also reported in another study with a bonobo, in which the bonobo was also able to synchronize its drum beats to a human in the experiment.
Movements from primates in these studies are not as precise as humans, but one hypothesis used to explain the origins of music could help explain the differences. It suggests that in humans, our ability to move in time with a beat stems from vocal learning. It could be that humans' ability to refine that beat synchronization evolved along with our vocalization abilities, Hattori said.
'The monkeys are a more distant evolutionary distant species, and so perhaps that there is some gradual development in the course of primate evolution,' Hattori told Salon in a video call.
This hypothesis could explain why birds like Snowball and humans can move to a rhythm, although it raises questions about Ronan the sea lion's ability to move to the beat. Sea lions don't naturally adapt their calls to external stimuli in the wild, although seals do, which share an evolutionary root with sea lions more than 20 million years up the ancestral tree. However, it could be that this shared ancestor is related to some degree of vocal learning in sea lions.
It's rare to get a brain scan of chimpanzees or sea lions due to ethical reasons, so what is happening neurologically when these animals move to the music is also unknown. However, experiments in birds like the zebra finch help provide some answers as to why this species sings.
Although zebra finches sing their own songs and do not move to external rhythms, they do at some point learn those songs from other zebra finches, so there is some degree of learning and internalization related to music.
In one 2017 study, Ofer Tchernichovski, who studies animal behavior at Hunter College, and his team set up an experiment in which birds had to get an unpleasant air puff in order to reach a peep hole where they could see a singing bird. What they found was that males were always willing to 'pay' to hear any song, whereas females were only willing to hear the song if they were presented with the song of their mate. When females were presented with the song of her mate, dopamine levels went up.
'The thing is, the females are not very sensitive to songs, so this was exactly the opposite of what we thought,' Tchernichovski told Salon in a video call. 'What we think is that for females, the song is really about sex, whereas for male zebra finches, it's more social.'
Another study released earlier this year found dopamine activity increased in young zebra finches when they sang songs that were closer to their eventual adult song versions compared to when they sang songs that deviated further away from them.
Other studies have shown male zebra finches 'self-evaluate' their songs when practicing alone with songs they sing better activating the dopamine system more than songs they sing worse. However, when singing for females, their dopamine system is activated by a social response based on the cues they receive from the female.
Studies show that the dopamine system in humans is also activated when we listen to music. In one study, people listened to their favorite music while under an fMRI machine. In anticipation of that moment, the dopamine system was activated in the brain.
Furthermore, studies have also shown that musical training in adolescence increases empathy and prosocial behaviors. In other words, it brings us together — which we see when we clap to the beat at a concert or sing the lyrics to popular songs. One 2014 study found infants were more likely to help someone if that person rocked them synchronously versus whether they did so out of rhythm.
'One of the theories that is important for the origins of musicality is that it could be a way of social bonding, of increasing the social cohesion of the group,' Honing said. 'You see the same thing with Snowball: He likes to dance when his owner is there … She always dances with him, and that's what the bird likes.'
'Enjoyment is the key,' Honing added. 'If you get pleasure out of something, that means it's important biologically, so it might be an adaptation.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Olivia Munn Reflects On Being Blamed For Aaron Rodgers' Family Drama
Olivia Munn is trying to set the record straight. The 'Your Friends & Neighbors' actor addressed long-standing rumors she was at the root of ex-boyfriend Aaron Rodgers' estrangement from his family during the Monday episode of 'Armchair Expert with Dax Shepard.' Though many blamed Rodgers' rift with his family on Munn during their three-year relationship, the star said she was not a factor in the falling out. 'There's this whole big narrative that stayed with me for so many years, but there was just this dynamic in the family that had nothing to do with me,' she explained. 'It became this whole big thing, and people were like, 'I can't believe her, she's keeping this family apart.'' While Munn said she did have insight into the family feud, she told Shepard it wasn't her business to share. 'People have speculated for many years what was the rift,' she said, 'and I know, but I'm not saying because it's not my story to tell.' Rodgers defended Munn in interviews for the 2024 book 'Out of the Darkness: The Mystery of Aaron Rodgers,' where he told author Ian O'Connor that his ex had 'nothing to do with all the years' of 'deep rooted' tension in his family. The star of 'The Newsroom' said she appreciated him speaking up, even if some people refuse to accept his explanation. 'You've been asking for the longest time. This is the constant conversation. The man himself is saying it. They don't want that answer,' she told Shepard, adding, 'I was really grateful that he did that. Even if people didn't want to take hold of that statement, it made me feel good that it was said.' Aaron Rodgers Says He's Married. So Who's The Lucky Gal? Aaron Rodgers Agrees To 1-Year Deal With New Team Danica Patrick Calls Relationship With Aaron Rodgers 'Emotionally Abusive'
Yahoo
32 minutes ago
- Yahoo
AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline
AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1bn, adding a 'high-risk, high-reward' clinical-stage in vivo CAR-T candidate to its pipeline. Capstan is developing a new type of CAR-T therapy that overcomes limitations with current options. Currently approved therapies of this kind act by upgrading patient-extracted T cells' ability to fight cancer cells, but this method has financial and scalability hurdles, along with a lymphodepleting chemo requirement, curbing uptake. Capstan's lead asset, CPTX2309, is an in vivo targeted lipid nanoparticle (LNP) anti-CD19 CAR-T therapy that could solve these issues. AbbVie certainly sees the promise in the drug, paying $2.1bn upfront to take control of the CAR-T therapy alongside other preclinical programmes and the RNA payload-delivering technology used to create them. CPTX2309, being developed for the treatment of B-cell-mediated autoimmune diseases, is already being evaluated in a Phase I study (NCT06917742) with healthy volunteers. A preliminary look at the data from Capstan has revealed strong B-cell depletion – the aim of the treatment is to achieve an 'immune reset' by repopulation of healthy B cells. Investors shared positive sentiment in the acquisition, with shares in NYSE-listed AbbVie closing 1.7% higher at $185.62 on 30 June, the day the announcement was made. The big pharma has a market cap of $327.9bn. This is not the first in vivo CAR-T relationship that AbbVie has fostered, with a collaboration with Umoja Biopharma in January 2024. This partnership allows AbbVie to develop in-situ generated CAR-T cell therapy candidates in oncology using Umoja's VivoVecplatform. William Blair analyst Matt Phipps said in a research note: 'While CPTX2309 is still in early clinical development, we believe the acquisition shows a strategic effort by AbbVie to further strengthen its immunology franchise through novel, disease-modifying mechanisms. 'Given the stage of development, this asset clearly comes with clinical risk, but given the potential of in vivo CAR-T, which does not require lymphodepletion and has potential for greater manufacturing scalability, it offers significant long-term upside if successful.' Phipps, who described AbbVie's new asset as 'high-risk, high-reward,' said the purchase consolidates AbbVie's strong trading. The big pharma company has already shrugged off the loss of market exclusivity for its blockbuster Humira (adalimumab) by rolling out Skyrizi (risankizumab) and Rinvoq (upadacitinib). According to William Blair, forecast revenue rate from 2024 to 2029 growth rate for AbbVie trails only Eli Lilly and Sanofi, representing an 'attractive opportunity' for long-term investors. Capstan's CEO Laura Shawver said: "In vivo CAR-T represents a potential new treatment modality in medicine – embodying the transformative power of cell therapy with the accessibility and scalability of an off-the-shelf biologic. This technology has the potential to become a first-in-class platform to treat a wide range of autoimmune diseases.' Interius BioTherapeutics and Umoja Biopharma are two biotechs in the in vivo CAR-T arena that have assets in clinical trials targeting oncological indications. These assets also use lentiviral vectors to generate the cells in vivo, whereas Capstan is using mRNA. CPTX2309 is built on Capstan's targeted LNP platform to enable in vivo delivery of RNA payloads to target cells. CPTX2309 is made up of an anti-CD19 CAR mRNA payload inside an LNP. AbbVie's purchase comes just a few days after the US Food and Drug Administration (FDA) removed an access barrier for currently approved CAR-T therapies, regarded as a boost to the sector's outlook. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. "AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., July 01, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced the second positive recommendation by an independent Data Safety Monitoring Board (DSMB) to continue, without modification, the SERENITY At-Home pivotal Phase 3 safety trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia. The DSMB recommendation followed a review of unblinded safety data from 178 patients dosed as of the May 28, 2025 cutoff date. The trial is fully enrolled and collection of data over the 12-week period is continuing. 'We are pleased with this additional favorable recommendation from the DSMB regarding our first at-home trial of BXCL501 and look forward to the upcoming data readout,' said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. 'Bipolar and schizophrenia-related agitation in the at-home setting is a large, unmet medical need, with no FDA-approved therapies. We are highly motivated to address this need for millions of patients, with trial data intended to support a potential sNDA submission to expand the IGALMI® label in the at-home setting.' The SERENITY At-Home Phase 3 trial is designed as a double-blind, placebo-controlled study to evaluate the safety of a 120 mcg dose of BXCL501 in 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting. Trial enrollment was completed in May, 2025 Topline data expected in Q3 2025. Additional information on the SERENITY At-Home trial is included in a corporate presentation in the Investors section of the Company's website: About BXCL501Outside of its approved indication by the U.S. Food and Drug Administration as IGALMI® (dexmedetomidine) sublingual film, BXCL501 is an investigational proprietary, orally dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist. BXCL501 is under investigation by BioXcel Therapeutics for the acute treatment of agitation associated with Alzheimer's dementia and for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in the at-home setting. The safety and efficacy of BXCL501 for these investigational uses have not been established. BXCL501 has been granted Breakthrough Therapy designation by the FDA for the acute treatment of agitation associated with dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders, and dementia. About the SERENITY At-Home Phase 3 TrialThe SERENITY At-Home Phase 3 trial is a double-blind, placebo-controlled study designed to evaluate the safety of a 120 mcg dose of BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting. The trial is designed to evaluate 200 patients with a history of agitation episodes residing at home either alone or with caregivers/informants. Patients are self-administering 120 mcg of BXCL501 or placebo when agitation episodes occur over the 12-week trial period, with safety data (adverse events) collected during the trial. In addition, patients or caregivers/informants will complete a modified global impression of severity (mCGIs) and a clinical global impression of change (mCGI-C) two hours after dosing as exploratory endpoints to evaluate use in the outpatient setting. About IGALMI® (dexmedetomidine) sublingual film INDICATION IGALMI® (dexmedetomidine) sublingual film is a prescription medicine, administered under the supervision of a health care provider, that is placed under the tongue or behind the lower lip and is used for the acute treatment of agitation associated with schizophrenia and bipolar disorder I or II in adults. The safety and effectiveness of IGALMI has not been studied beyond 24 hours from the first dose. It is not known if IGALMI is safe and effective in children. IMPORTANT SAFETY INFORMATION IGALMI can cause serious side effects, including: Decreased blood pressure, low blood pressure upon standing, and slower than normal heart rate, which may be more likely in patients with low blood volume, diabetes, chronic high blood pressure, and older patients. IGALMI is taken under the supervision of a healthcare provider who will monitor vital signs (like blood pressure and heart rate) and alertness after IGALMI is administered to help prevent falling or fainting. Patients should be adequately hydrated and sit or lie down after taking IGALMI and instructed to tell their healthcare provider if they feel dizzy, lightheaded, or faint. Heart rhythm changes (QT interval prolongation). IGALMI should not be given to patients with an abnormal heart rhythm, a history of an irregular heartbeat, slow heart rate, low potassium, low magnesium, or taking other drugs that could affect heart rhythm. Taking IGALMI with a history of abnormal heart rhythm can increase the risk of torsades de pointes and sudden death. Patients should be instructed to tell their healthcare provider immediately if they feel faint or have heart palpitations. Sleepiness/drowsiness. Patients should not perform activities requiring mental alertness, such as driving or operating hazardous machinery, for at least 8 hours after taking IGALMI. Withdrawal reactions, tolerance, and decreased response/efficacy. IGALMI was not studied for longer than 24 hours after the first dose. Physical dependence, withdrawal symptoms (e.g., nausea, vomiting, agitation), and decreased response to IGALMI may occur if IGALMI is used longer than 24 hours. The most common side effects of IGALMI in clinical studies were sleepiness or drowsiness, a prickling or tingling sensation or numbness of the mouth, dizziness, dry mouth, low blood pressure, and low blood pressure upon standing. These are not all the possible side effects of IGALMI. Patients should speak with their healthcare provider for medical advice about side effects. Patients should tell their healthcare provider about their medical history, including if they suffer from any known heart problems, low potassium, low magnesium, low blood pressure, low heart rate, diabetes, high blood pressure, history of fainting, or liver impairment. They should also tell their healthcare provider if they are pregnant or breastfeeding or take any medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Patients should especially tell their healthcare provider if they take any drugs that lower blood pressure, change heart rate, or take anesthetics, sedatives, hypnotics, and opioids. Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You can also contact BioXcel Therapeutics, Inc. at 1-833-201-1088 or medinfo@ Please see full prescribing information at About BioXcel Therapeutics, Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit Forward-Looking Statements This press release includes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to: the Company's planned advancement of its SERENITY trial; potential market opportunity for BXCL501; completing enrollment and release of topline data from the ongoing SERENITY trial; submission of an sNDA; expanding the IGALMI® label in the at-home setting; the potential for the results from the Company's completed, ongoing and proposed clinical trials to support regulatory approvals for its product candidates. When used herein, words including 'anticipate,' 'believe,' 'can,' 'continue,' 'could,' 'designed,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; the impact of the reprioritization; its significant indebtedness, ability to comply with covenant obligations and potential payment obligations related to such indebtedness and other contractual obligations; the Company has identified conditions and events that raise substantial doubt about its ability to continue as a going concern; its limited experience in drug discovery and drug development; risks related to the TRANQUILITY program; its dependence on the success and commercialization of IGALMI®, BXCL501, BXCL502, BXCL701 and BXCL702 and other product candidates; the number of episodes of agitation and the size of the Company's total addressable market may be overestimated, and approval that the Company may obtain may be based on a narrower definition of the patient population; its lack of experience in marketing and selling drug products; the risk that IGALMI or the Company's product candidates may not be accepted by physicians or the medical community in general; the Company still faces extensive and ongoing regulatory requirements and obligations for IGALMI; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects caused by the Company's product candidates; its novel approach to the discovery and development of product candidates based on EvolverAI; the significant influence of and dependence on BioXcel LLC; its exposure to patent infringement lawsuits; its reliance on third parties; its ability to comply with the extensive regulations applicable to it; impacts from data breaches or cyber-attacks, if any; risks associated with the increased scrutiny relating to environmental, social and governance (ESG) matters; risks associated with federal, state or foreign health care 'fraud and abuse' laws; and its ability to commercialize its product candidates, as well as the important factors discussed under the caption 'Risk Factors' in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC's website at and the Investors section of the Company's website at These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release. Contact Information InvestorsRusso PartnersNic Johnson1.303.482.6405 MediaRusso PartnersDavid Schull1.858.717.2310 Source: BioXcel Therapeutics, is a registered trademark of BioXcel Therapeutics, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data